Related references
Note: Only part of the references are listed.Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Lara A. Dunn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
The Current Histologic Classification of Thyroid Cancer
Sylvia L. Asa
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2019)
Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma
Ju Hye Jeong et al.
THYROID (2019)
KRAS G12V Mutation in Acquired resistance to Combined BRAF and MEK Inhibition in Papilary Thyroid Cancer
Dwight H. Owen et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo
Koji Tsumagari et al.
ENDOCRINE-RELATED CANCER (2018)
BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy
Douglas B. Johnson et al.
PIGMENT CELL & MELANOMA RESEARCH (2018)
IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells
Tiziana Notarangelo et al.
CANCER LETTERS (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines
Yongsheng Jia et al.
ONCOLOGY LETTERS (2018)
The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
Hao Song et al.
MEDICAL SCIENCE MONITOR (2018)
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations
Tali Ofir Dovrat et al.
CANCER BIOLOGY & THERAPY (2018)
Therapeutic advances in anaplastic thyroid cancer: a current perspective
Shikha Saini et al.
MOLECULAR CANCER (2018)
Evaluation of the Role of BRAFV600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study
Luca Damiani et al.
EUROPEAN THYROID JOURNAL (2018)
Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
Honglai Zhang et al.
THYROID RESEARCH (2018)
Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer
William J. Gibson et al.
CLINICAL CANCER RESEARCH (2017)
Molecular diagnosis in type I epithelial ovarian cancer
Pawel Sadlecki et al.
GINEKOLOGIA POLSKA (2017)
Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
Dagmara Rusinek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors
Matthias A. Roelli et al.
ONCOTARGET (2017)
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E
Zeus A. Antonello et al.
ONCOTARGET (2017)
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Tiziana Notarangelo et al.
CANCER CELL INTERNATIONAL (2017)
BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma
Atul Kulkarni et al.
CLINICAL CANCER RESEARCH (2017)
The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies
Roy Lirov et al.
DRUGS (2017)
Targeted Therapy in Thyroid Cancer: State of the Art
L. Valerio et al.
CLINICAL ONCOLOGY (2017)
ENDOCRINE TUMOURS Genetic predictors of thyroid cancer outcome
Catarina Tavares et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Jeffrey S. Ross et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
c-Met-Mediated Reactivation of PI3K/AKT Signaling Contributes to Insensitivity of BRAF(V600E) Mutant Thyroid Cancer to BRAF Inhibition
Hyung Kwon Byeon et al.
MOLECULAR CARCINOGENESIS (2016)
B-Raf Inhibition in the Clinic: Present and Future
Warren Fiskus et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells
Weiwei Cheng et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis
Chunping Liu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2016)
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen et al.
CANCER DISCOVERY (2016)
Long-Term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model
Brian P. Danysh et al.
ONCOTARGET (2016)
BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence
Agnieszka Czarniecka et al.
GLAND SURGERY (2016)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer
Severine M. Niederer-Wuest et al.
SURGERY (2015)
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Gerald S. Falchook et al.
THYROID (2015)
mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
Elyse K. Hanly et al.
ONCOTARGET (2015)
Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model
Mark Duquette et al.
ONCOTARGET (2015)
BRAF gene: From human cancers to developmental syndromes
Muhammad Ramzan Manwar Hussain et al.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2015)
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg et al.
CLINICAL CANCER RESEARCH (2015)
BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity
M. E. Cabanillas et al.
HORMONES & CANCER (2015)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
BRAF inhibitors in cancer therapy
Carolina Hertzman Johansson et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors
Martin L. Sos et al.
CELL REPORTS (2014)
Does BRAF V600E Mutation Predict Aggressive Features in Papillary Thyroid Cancer? Results From Four Endocrine Surgery Centers
Carol Li et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review
Anna Guerra et al.
BMC SURGERY (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Molecular pathogenesis and mechanisms of thyroid cancer
Mingzhao Xing
NATURE REVIEWS CANCER (2013)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
New driver mutations in non-small-cell lung cancer
William Pao et al.
LANCET ONCOLOGY (2011)
Epidermal Growth Factor Receptor 1 Expression Is Upregulated in Undifferentiated Thyroid Carcinomas in Humans
Matteo Landriscina et al.
THYROID (2011)
Well-Differentiated Thyroid Carcinomas: Management of the Central Lymph Node Compartment and Emerging Biochemical Markers
Meei J. Yeung et al.
JOURNAL OF ONCOLOGY (2011)
BRAF, a Target in Melanoma Implications for Solid Tumor Drug Development
Keith T. Flaherty et al.
CANCER (2010)
BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications
Kam-Tsun Tang et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2010)
Molecular characteristics in papillary thyroid cancers (PTCs) with no I-131 uptake
Caterina Mian et al.
CLINICAL ENDOCRINOLOGY (2008)
BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma:: A 15-year median follow-up study
Rossella Elisei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Extensive clinical experience - Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma
Cristiana Lupi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Raf kinases: Function, regulation and role in human cancer
Deborah T. Leicht et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism
C. Durante et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant
Dingxie Liu et al.
CLINICAL CANCER RESEARCH (2007)
Targeting BRAF in thyroid cancer
A. V. Espinosa et al.
BRITISH JOURNAL OF CANCER (2007)
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer
Shuiying Hu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
RET/PTC activation in papillary thyroid carcinoma: European journal of endocrinology prize lecture
Massimo Santoro et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas
Vitor Trovisco et al.
HUMAN PATHOLOGY (2006)
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
T Kondo et al.
NATURE REVIEWS CANCER (2006)
Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns - A clinicopathologic study of 183 patients
M Volante et al.
CANCER (2004)
Medullary thyroid carcinoma
S Leboulleux et al.
CLINICAL ENDOCRINOLOGY (2004)
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
F Chang et al.
LEUKEMIA (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Positive and negative regulation of Raf kinase activity and function by phosphorylation
H Chong et al.
EMBO JOURNAL (2001)
Share Paper
